Gavin Giovannoni

List of Publications by Year
in descending order

		11651	6996
398 papers	27,325 citations	70 h-index	154 g-index
413 all docs	413 docs citations	413 times ranked	18451 citing authors

#	Article	IF	Citations
1	A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2006, 354, 899-910.	27.0	2,916
2	Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2012, 367, 1098-1107.	27.0	1,493
3	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 209-220.	27.0	1,324
4	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 221-234.	27.0	1,322
5	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1819-1828.	13.7	1,041
6	A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2010, 362, 416-426.	27.0	791
7	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	13.7	684
8	Meta‑analysis of early nonmotor features and risk factors for Parkinson disease. Annals of Neurology, 2012, 72, 893-901.	5.3	607
9	Recommended Standard of Cerebrospinal Fluid Analysis in the Diagnosis of Multiple Sclerosis. Archives of Neurology, 2005, 62, 865-70.	4.5	483
10	Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurology, The, 2010, 9, 727-739.	10.2	459
11	Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurology, The, 2009, 8, 254-260.	10.2	430
12	Neurofilament light chain. Neurology, 2015, 84, 2247-2257.	1.1	412
13	Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases. PLoS ONE, 2013, 8, e75091.	2.5	375
14	Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain, 2003, 126, 2191-2202.	7.6	330
15	Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nature Medicine, 2007, 13, 492-497.	30.7	326
16	Brain health: time matters in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 9, S5-S48.	2.0	280
17	Is it time to target no evident disease activity (NEDA) in multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2015, 4, 329-333.	2.0	275
18	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2013, 381, 2167-2175.	13.7	269

#	Article	IF	Citations
19	An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis. PLoS ONE, 2010, 5, e12496.	2.5	260
20	Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurology, 2020, 77, 1132.	9.0	245
21	Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. New England Journal of Medicine, 2018, 379, 1017-1027.	27.0	237
22	Alemtuzumab CARE-MS II 5-year follow-up. Neurology, 2017, 89, 1117-1126.	1.1	232
23	Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple Sclerosis Journal, 2018, 24, 1594-1604.	3.0	227
24	Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine, 2017, 16, 41-50.	6.1	225
25	Smoking and Multiple Sclerosis: An Updated Meta-Analysis. PLoS ONE, 2011, 6, e16149.	2.5	220
26	Human Endogenous Retroviruses in Neurological Diseases. Trends in Molecular Medicine, 2018, 24, 379-394.	6.7	212
27	Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. JAMA Neurology, 2017, 74, 961.	9.0	204
28	Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurology, The, 2011, 10, 329-337.	10.2	199
29	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. Journal of Neurology, 2009, 256, 405-415.	3.6	193
30	Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies. Annals of Neurology, 2001, 50, 588-595.	5.3	189
31	Alemtuzumab CARE-MS I 5-year follow-up. Neurology, 2017, 89, 1107-1116.	1.1	188
32	Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. Trends in Molecular Medicine, 2020, 26, 296-310.	6.7	178
33	Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 298-304.	1.9	171
34	Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Practical Neurology, 2015, 15, 273-279.	1.1	169
35	Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2016, 15, 259-269.	10.2	168
36	Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology, 2017, 88, 826-831.	1.1	168

#	Article	IF	Citations
37	Optimizing treatment success in multiple sclerosis. Journal of Neurology, 2016, 263, 1053-1065.	3.6	155
38	Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology, 2015, 84, 1639-1643.	1.1	153
39	The COVID-19 pandemic and the use of MS disease-modifying therapies. Multiple Sclerosis and Related Disorders, 2020, 39, 102073.	2.0	153
40	Infectious causes of multiple sclerosis. Lancet Neurology, The, 2006, 5, 887-894.	10.2	151
41	Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 273-279.	1.9	144
42	Multiple sclerosis: the environment and causation. Current Opinion in Neurology, 2007, 20, 261-268.	3.6	143
43	The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Multiple Sclerosis Journal, 2013, 19, 162-166.	3.0	139
44	Fingolimod modulates microglial activation to augment markers of remyelination. Journal of Neuroinflammation, 2011, 8, 76.	7.2	127
45	â€œNo evident disease activityâ€: The use of combined assessments in the management of patients with multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1179-1187.	3.0	126
46	Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. Journal of Neurology, 2018, 265, 1199-1209.	3.6	120
47	<scp>COVID</scp>â€19 Vaccine Response in People with Multiple Sclerosis. Annals of Neurology, 2022, 91, 89-100.	5.3	119
48	UK consensus on pregnancy in multiple sclerosis: â€˜Association of British Neurologistsâ€™ guidelines. Practical Neurology, 2019, 19, 106-114.	1.1	118
49	Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. Current Opinion in Neurology, 2018, 31, 233-243.	3.6	116
50	Switching from natalizumab to fingolimod. Neurology, 2015, 85, 29-39.	1.1	110
51	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2019, 18, 845-856.	10.2	110
52	Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group. Multiple Sclerosis and Related Disorders, 2018, 19, 153-160.	2.0	101
53	Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 29, 168-174.	2.0	94
54	Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. Multiple Sclerosis and Related Disorders, 2019, 29, 157-167.	2.0	94

#	Article	IF	Citations
55	Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Multiple Sclerosis and Related Disorders, 2017, 12, 70-78.	2.0	92
56	Cladribine to Treat Relapsing Forms of Multiple Sclerosis. Neurotherapeutics, 2017, 14, 874-887.	4.4	92
57	Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. Journal of Neuroimmunology, 2008, 193, 120-129.	2.3	91
58	Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 565-573.	1.9	91
59	PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 31-37.	1.9	90
60	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	1.9	90
61	The Multiple Sclerosis Care Unit. Multiple Sclerosis Journal, 2019, 25, 627-636.	3.0	90
62	Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom. BMC Public Health, 2020, 20, 912.	2.9	90
63	Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31.	1.4	86
64	Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. Multiple Sclerosis and Related Disorders, 2015, 4, 202-218.	2.0	85
65	No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis. Advances in Therapy, 2014, 31, 1134-1154.	2.9	83
66	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurology, The, 2014, 13, 472-481.	10.2	83
67	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. Lancet Neurology, The, 2020, 19, 214-225.	10.2	81
68	Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects. Drugs, 2021, 81, 207-231.	10.9	81
69	Multiple sclerosis: a practical overview for clinicians. British Medical Bulletin, 2010, 95, 79-104.	6.9	80
70	HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 9-12.	1.9	77
71	Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641985498.	3.5	76
72	The clinical significance of an intrathecal monoclonal immunoglobulin band. Neurology, 2003, 60, 1163-1166.	1.1	72

#	Article	IF	Citations
73	Smouldering multiple sclerosis: the 'real MS'. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642110667.	3.5	72
74	Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. Journal of Neuroimmunology, 2005, 165, 41-52.	2.3	70
75	Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy. Biosensors and Bioelectronics, 2015, 68, 660-667.	10.1	69
76	No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation. Journal of Neurology, 2018, 265, 1089-1095.	3.6	67
77	BMI and low vitamin D are causal factors for multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	67
78	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 988-997.	10.2	64
79	Siponimod and Cognition in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 96, e376-e386.	1.1	64
80	e-Health and multiple sclerosis: An update. Multiple Sclerosis Journal, 2018, 24, 1657-1664.	3.0	63
81	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study. Journal of Neurology, 2013, 260, 2297-2305.	3.6	62
82	The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Multiple Sclerosis and Related Disorders, 2020, 43, 102174.	2.0	62
83	Assessing treatment response to interferon-β. Neurology, 2014, 82, 248-254.	1.1	61
84	Cladribine: mechanisms and mysteries in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1266-1271.	1.9	61
85	Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Multiple Sclerosis and Related Disorders, 2012, 1, 29-38.	2.0	60
86	Editors' welcome and a working definition for a multiple sclerosis cure. Multiple Sclerosis and Related Disorders, 2013, 2, 65-67.	2.0	59
87	PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease. Movement Disorders, 2017, 32, 219-226.	3.9	59
88	Parkinson's disease determinants, prediction and gene–environment interactions in the UK Biobank. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1046-1054.	1.9	59
89	Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNβ in multiple sclerosis patients. Journal of Immunological Methods, 2008, 336, 113-118.	1.4	57
90	Evaluating more naturalistic outcome measures. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e162.	6.0	57

#	Article	IF	Citations
91	Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS). Multiple Sclerosis Journal, 2015, 21, 57-66.	3.0	56
92	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology, 2016, 87, 1985-1992.	1.1	55
93	International consensus on quality standards for brain health-focused care in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1809-1818.	3.0	55
94	Systematic review and meta-analysis of the association between Epstein–Barr virus, multiple sclerosis and other risk factors. Multiple Sclerosis Journal, 2020, 26, 1281-1297.	3.0	55
95	The implications of immunogenicity for protein-based multiple sclerosis therapies. Journal of the Neurological Sciences, 2008, 275, 7-17.	0.6	54
96	Post–streptococcal autoimmune dystonia with isolated bilateral striatal necrosis. Developmental Medicine and Child Neurology, 2002, 44, 485-489.	2.1	52
97	Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Multiple Sclerosis Journal, 2011, 17, 939-948.	3.0	52
98	Bradykinesia-Akinesia Incoordination Test: Validating an Online Keyboard Test of Upper Limb Function. PLoS ONE, 2014, 9, e96260.	2.5	52
99	Multiple Sclerosis Cerebrospinal Fluid Biomarkers. Disease Markers, 2006, 22, 187-196.	1.3	51
100	Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 274-278.	1.9	51
101	The bradykinesia akinesia incoordination test (BRAIN TESTï¿½), an objective and user-friendly means to evaluate patients with Parkinsonism. Movement Disorders, 2000, 15, 641-647.	3.9	49
102	Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS â€“ Neurofilament as a Surrogate of Disease Progression. PLoS ONE, 2013, 8, e70019.	2.5	48
103	Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Multiple Sclerosis and Related Disorders, 2016, 9, 36-46.	2.0	48
104	The effects of intrathecal rituximab on biomarkers in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 6, 49-53.	2.0	47
105	Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Multiple Sclerosis Journal, 2018, 24, 222-226.	3.0	47
106	Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. International Journal of MS Care, 2015, 17, 236-243.	1.0	47
107	MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. Journal of Neurology, 2013, 260, 1136-1146.	3.6	46
108	Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Multiple Sclerosis Journal, 2019, 25, 819-827.	3.0	46

#	Article	IF	Citations
109	Epstein–Barr virus and multiple sclerosis: association or causation?. Expert Review of Neurotherapeutics, 2013, 13, 287-297.	2.8	45
110	Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628561775336.	3.5	45
111	The importance of a multi-disciplinary perspective and patient activation programmes in MS management. Multiple Sclerosis Journal, 2016, 22, 34-46.	3.0	44
112	Pediatric multiple sclerosis. Neurology, 2016, 87, S103-9.	1.1	44
113	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurology, The, 2022, 21, 608-619.	10.2	44
114	The McDonald Criteria for Multiple Sclerosis: time for clarification. Multiple Sclerosis Journal, 2010, 16, 566-575.	3.0	43
115	Therapies for multiple sclerosis: considerations in the pediatric patient. Nature Reviews Neurology, 2011, 7, 109-122.	10.1	43
116	Genetic Background Can Result in a Marked or Minimal Effect of Gene Knockout (GPR55 and CB2) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2013, 8, e76907.	2.5	43
117	Depletion of <scp>CD</scp>52–positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune–tolerance promoting <scp>CD</scp>8 T–cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis. Immunology, 2017, 150, 444-455.	4.4	43
118	Vitamin D supplementation. Practical Neurology, 2018, 18, 35-42.	1.1	43
119	Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis. Brain, 2018, 141, 2834-2847.	7.6	43
120	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. BMJ Open, 2018, 8, e021944.	1.9	43
121	Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids. Journal of NeuroImmune Pharmacology, 2015, 10, 281-292.	4.1	42
122	Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology, 2018, 84, 527-536.	5.3	42
123	Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19. Multiple Sclerosis and Related Disorders, 2020, 41, 102135.	2.0	42
124	Elevated salivary protein in Parkinson's disease and salivary DJ-1 as a potential marker of disease severity. Parkinsonism and Related Disorders, 2015, 21, 1251-1255.	2.2	41
125	Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal, 2018, 24, 1862-1870.	3.0	41
126	Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurology, 2016, 16, 117.	1.8	40

#	Article	IF	Citations
127	A brief history of NEDA. Multiple Sclerosis and Related Disorders, 2018, 20, 228-230.	2.0	40
128	Protecting people with multiple sclerosis through vaccination. Practical Neurology, 2020, 20, 435.1-445.	1.1	40
129	Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. Practical Neurology, 2016, 16, 389-393.	1.1	39
130	Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1β. Journal of Neuroinflammation, 2017, 14, 131.	7.2	39
131	Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clinical Therapeutics, 2007, 29, 1128-1145.	2.5	38
132	The diagnostic criteria for multiple sclerosis: From Charcot to McDonald. Multiple Sclerosis and Related Disorders, 2012, 1, 9-14.	2.0	37
133	Screening performance of abbreviated versions of the UPSIT smell test. Journal of Neurology, 2019, 266, 1897-1906.	3.6	37
134	Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis. Brain, 2014, 137, 92-108.	7.6	36
135	Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies. Clinical Therapeutics, 2014, 36, 1958-1971.	2.5	36
136	Increased expression of colony–stimulating factor–1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss. Glia, 2018, 66, 2108-2125.	4.9	36
137	Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 46, 102572.	2.0	36
138	Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis. Journal of Neurology, 2013, 260, 2505-2510.	3.6	35
139	Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e202.	6.0	34
140	Neural cell adhesion molecules in brain plasticity and disease. Multiple Sclerosis and Related Disorders, 2013, 2, 13-20.	2.0	33
141	Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. Neurology and Therapy, 2016, 5, 45-57.	3.2	33
142	Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment. Multiple Sclerosis and Related Disorders, 2017, 18, 181-183.	2.0	33
143	Epstein-Barr–negative MS: a true phenomenon?. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e318.	6.0	33
144	Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. Journal of Neuroimmunology, 2021, 357, 577627.	2.3	33

#	Article	IF	Citations
145	The Rebif® New Formulation Story. Drugs in R and D, 2007, 8, 335-348.	2.2	32
146	Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1355-1362.	3.0	32
147	Control of spasticity in a multiple sclerosis model using central nervous system–excluded CB$_1$ cannabinoid receptor agonists. FASEB Journal, 2014, 28, 117-130.	0.5	32
148	Alemtuzumab depletion failure can occur in multiple sclerosis. Immunology, 2018, 154, 253-260.	4.4	32
149	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876064.	1.0	32
150	Gene-Environment Interactions in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	32
151	Neuroprotection in a Novel Mouse Model of Multiple Sclerosis. PLoS ONE, 2013, 8, e79188.	2.5	32
152	Antineuronal antibody status and phenotype analysis in Tourette's syndrome. Movement Disorders, 2007, 22, 1424-1429.	3.9	31
153	Cerebrospinal fluid analysis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 681-702.	1.8	31
154	Neural cell adhesion molecule – Description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders. Journal of Neuroimmunology, 2010, 225, 118-122.	2.3	30
155	Epstein–Barr virus, latitude and multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 362-365.	3.0	30
156	Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. Multiple Sclerosis and Related Disorders, 2014, 3, 705-711.	2.0	30
157	A practical review of the neuropathology and neuroimaging of multiple sclerosis. Practical Neurology, 2016, 16, 279-287.	1.1	30
158	Cladribine tablets for relapsing–remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. Multiple Sclerosis and Related Disorders, 2012, 1, 49-54.	2.0	29
159	The neurodegenerative prodrome in multiple sclerosis. Lancet Neurology, The, 2017, 16, 413-414.	10.2	29
160	Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon. CNS and Neurological Disorders - Drug Targets, 2012, 11, 610-623.	1.4	29
161	The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2012, 1, 64-75.	2.0	28
162	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS. Neurology, 2016, 87, 1464-1472.	1.1	28

#	Article	IF	Citations
163	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. Neurology, 2020, 95, e1027-e1040.	1.1	28
164	Multiple sclerosis outpatient future groups: improving the quality of participant interaction and ideation tools within service improvement activities. BMC Health Services Research, 2015, 15, 105.	2.2	27
165	Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. Acta Neuropathologica Communications, 2013, 1, 84.	5.2	26
166	Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clinical Therapeutics, 2017, 39, 1671-1679.	2.5	26
167	Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1367-1376.	3.0	26
168	Peripheral blood neurofilament light chain levels: the neurologist's C-reactive protein?. Brain, 2018, 141, 2235-2237.	7.6	26
169	Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG*MS* study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 483-492.	1.9	26
170	Enzymatic degradation of RNA causes widespread protein aggregation in cell and tissue lysates. EMBO Reports, 2020, 21, e49585.	4.5	26
171	Disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Multiple Sclerosis Journal, 2014, 20, 464-470.	3.0	25
172	Personalized medicine in multiple sclerosis. Neurodegenerative Disease Management, 2017, 7, 13-17.	2.2	25
173	A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. Multiple Sclerosis and Related Disorders, 2018, 24, 123-128.	2.0	25
174	Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population. JAMA Neurology, 2022, 79, 359.	9.0	25
175	Bone health in chronic neurological diseases: a focus on multiple sclerosis and parkinsonian syndromes. Practical Neurology, 2013, 13, 70-79.	1.1	24
176	Multiple sclerosis in the Iranian immigrant population of BC, Canada: prevalence and risk factors. Multiple Sclerosis Journal, 2014, 20, 1182-1188.	3.0	24
177	Gender identity disorders and multiple sclerosis risk: A national record-linkage study. Multiple Sclerosis Journal, 2016, 22, 1759-1762.	3.0	24
178	Cerebrospinal Fluid Biomarkers in Human Spinal Cord Injury from a Phase II Minocycline Trial. Journal of Neurotrauma, 2018, 35, 1918-1928.	3.4	24
179	A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis. Neurology and Therapy, 2020, 9, 359-374.	3.2	24
180	Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier. Neurology and Therapy, 2018, 7, 179-187.	3.2	23

#	ARTICLE	IF	CITATIONS
181	Expert opinion on the use of cladribine tablets in clinical practice. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093501.	3.5	23
182	Strategies to treat and prevent the development of neutralizing anti-interferon-Î² antibodies. Neurology, 2003, 61, S13-7.	1.1	23
183	Management of Secondary-Progressive Multiple Sclerosis. CNS Drugs, 2004, 18, 653-669.	5.9	22
184	Big conductance calciumâ€‐activated potassium channel openers control spasticity without sedation. British Journal of Pharmacology, 2017, 174, 2662-2681.	5.4	22
185	Cladribine Tablets for Relapsingâ€“Remitting Multiple Sclerosis: A Clinicianâ€™s Review. Neurology and Therapy, 2022, 11, 571-595.	3.2	22
186	Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysis. Multiple Sclerosis and Related Disorders, 2020, 44, 102241.	2.0	21
187	The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies. Frontiers in Immunology, 2020, 11, 124.	4.8	21
188	Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk. Annals of Neurology, 2020, 87, 599-608.	5.3	21
189	Psychiatric disorders in children with demyelinating diseases of the central nervous system. Multiple Sclerosis Journal, 2018, 24, 1243-1250.	3.0	20
190	Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care. Advances in Therapy, 2019, 36, 3238-3252.	2.9	20
191	Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. Drug Safety, 2020, 43, 635-643.	3.2	20
192	A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). Health Technology Assessment, 2017, 21, 1-50.	2.8	20
193	Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the â€˜Spinal Tapâ€™. Multiple Sclerosis Journal, 2010, 16, 285-286.	3.0	19
194	Alcohol Misuse Disorders and Multiple Sclerosis Risk. JAMA Neurology, 2014, 71, 1188.	9.0	19
195	Subtle motor disturbances in PREDICT-PD participants. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 212-217.	1.9	19
196	Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course. International Journal of MS Care, 2012, 14, 105-114.	1.0	19
197	CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103448.	2.0	19
198	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5â€‰years. Multiple Sclerosis Journal, 2022, 28, 1591-1605.	3.0	19

#	Article	IF	Citations
199	After the storm. Neurology, 2011, 76, 1200-1201.	1.1	18
200	Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. Journal of Neurology, 2014, 261, 316-323.	3.6	18
201	The role of infections in Behçet disease and neuro-Behçet syndrome. Autoimmunity Reviews, 2015, 14, 609-615.	5.8	18
202	Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis. Multiple Sclerosis and Related Disorders, 2017, 14, 46-50.	2.0	18
203	Science is 1% inspiration and 99% biomarkers. Multiple Sclerosis Journal, 2017, 23, 1442-1452.	3.0	18
204	No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Multiple Sclerosis Journal, 2017, 23, 1736-1747.	3.0	18
205	Learning ability correlates with brain atrophy and disability progression in RRMS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 38-43.	1.9	18
206	Antineuronal antibodies in Parkinson's disease. Movement Disorders, 2008, 23, 958-963.	3.9	17
207	Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United Kingdom. JAMA Neurology, 2016, 73, 954.	9.0	17
208	The Potential for EBV Vaccines to Prevent Multiple Sclerosis. Frontiers in Neurology, 0, 13, .	2.4	17
209	Natalizumab to fingolimod washout in patients at risk of PML. Neurology, 2014, 82, 1196-1197.	1.1	16
210	Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy—YES. Multiple Sclerosis Journal, 2016, 22, 1397-1400.	3.0	16
211	Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis. Annals of Clinical and Translational Neurology, 2017, 4, 506-511.	3.7	16
212	Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine. Multiple Sclerosis and Related Disorders, 2018, 24, 20-27.	2.0	16
213	Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1564-1576.	3.0	16
214	Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. Multiple Sclerosis Journal, 2022, 28, 1526-1540.	3.0	16
215	Extended dosing of monoclonal antibodies in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 2001-2009.	3.0	16
216	Current and Future Role of Interferon Beta in the Therapy of Multiple Sclerosis. Journal of Interferon and Cytokine Research, 2010, 30, 715-726.	1.2	15

#	Article	IF	Citations
217	Individualizing treatment goals and interventions for people with MS. Current Opinion in Neurology, 2012, 25, S20-S27.	3.6	15
218	The Refinement of Genetic Predictors of Multiple Sclerosis. PLoS ONE, 2014, 9, e96578.	2.5	15
219	Multiple sclerosis therapy and Epstein–Barr virus antibody titres. Multiple Sclerosis and Related Disorders, 2014, 3, 372-374.	2.0	15
220	Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. Multiple Sclerosis Journal, 2022, 28, 111-120.	3.0	15
221	Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 295-302.	1.9	15
222	Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts. Multiple Sclerosis and Related Disorders, 2018, 25, 197-199.	2.0	14
223	Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5Âmg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies. Advances in Therapy, 2021, 38, 4975-4985.	2.9	14
224	Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?. Clinical and Experimental Immunology, 2022, 207, 263-271.	2.6	14
225	The 'Field Hypothesis': rebound activity after stopping disease-modifying therapies. Multiple Sclerosis and Related Disorders, 2017, 15, A1-A2.	2.0	13
226	The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis. Journal of Neurology, 2018, 265, 285-290.	3.6	13
227	Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 35, 19-25.	2.0	13
228	Visibility and representation of women in multiple sclerosis research. Neurology, 2019, 92, 713-719.	1.1	13
229	Improving estimation of Parkinson's disease risk—the enhanced PREDICT-PD algorithm. Npj Parkinson's Disease, 2021, 7, 33.	5.3	13
230	Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study. Multiple Sclerosis Journal, 2022, 28, 1219-1228.	3.0	13
231	Dementia risk in a diverse population: A single-region nested case-control study in the East End of London. Lancet Regional Health - Europe, The, 2022, 15, 100321.	5.6	13
232	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Multiple Sclerosis Journal, 2022, 28, 842-846.	3.0	13
233	CSF neurofilament light chain testing as an aid to determine treatment strategies in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e880.	6.0	12
234	COVID-19 vaccines and multiple sclerosis disease-modifying therapies. Multiple Sclerosis and Related Disorders, 2021, 53, 103155.	2.0	12

#	Article	IF	Citations
235	Chronic lesion activity and disability progression in secondary progressive multiple sclerosis. BMJ Neurology Open, 2022, 4, e000240.	1.6	12
236	Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis. Clinical Drug Investigation, 2012, 32, 15-27.	2.2	11
237	Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept. BMC Neurology, 2014, 14, 237.	1.8	11
238	CCSVI-A. A call to clinicans and scientists to vocalise in an Internet age. Multiple Sclerosis and Related Disorders, 2014, 3, 143-146.	2.0	11
239	The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2015, 4, 3-5.	2.0	11
240	A Risk Score for Predicting Multiple Sclerosis. PLoS ONE, 2016, 11, e0164992.	2.5	11
241	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-72.	0.7	11
242	Is EBV the cause of multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2022, 58, 103636.	2.0	11
243	Circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis. Annals of Neurology, 2000, 47, 684-685.	5.3	10
244	Primary CNS Mantle Cell Lymphoma Associated with an Isolated CSF Monoclonal IgG Band. European Neurology, 2003, 49, 187-188.	1.4	10
245	Should we rebrand multiple sclerosis a dementia?. Multiple Sclerosis and Related Disorders, 2017, 12, 79-81.	2.0	10
246	Women on multiple sclerosis clinical trial steering committees. Annals of Neurology, 2018, 84, 329-330.	5.3	10
247	Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies. Multiple Sclerosis and Related Disorders, 2019, 27, 247-253.	2.0	10
248	Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences, 2020, 417, 117079.	0.6	10
249	Implications of Low-Titer MOG Antibodies. Multiple Sclerosis and Related Disorders, 2022, 59, 103746.	2.0	10
250	The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. Multiple Sclerosis and Related Disorders, 2022, 61, 103757.	2.0	10
251	Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis–related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. Clinical Therapeutics, 2015, 37, 2543-2551.	2.5	9
252	IgG4-related disease: a rare but treatable cause of refractory intracranial hypertension. Practical Neurology, 2016, 16, 235-239.	1.1	9

#	ARTICLE	IF	CITATIONS
253	How long is the presymptomatic phase of multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2016, 7, 12-13.	2.0	9
254	Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 17, 32-40.	2.0	9
255	No Evident Disease Activity—More Than a Risky Ambition?. JAMA Neurology, 2018, 75, 781.	9.0	9
256	Estimated and projected burden of multiple sclerosis attributable to smoking and childhood and adolescent high body-mass index: a comparative risk assessment. International Journal of Epidemiology, 2021, 49, 2051-2057.	1.9	9
257	Predicting disability worsening in relapsing and progressive multiple sclerosis. Current Opinion in Neurology, 2021, 34, 312-321.	3.6	9
258	Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110582.	3.5	9
259	Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity. Biomarkers in Medicine, 2007, 1, 111-119.	1.4	8
260	Promising Emerging Therapies for Multiple Sclerosis. Neurologic Clinics, 2011, 29, 435-448.	1.8	8
261	Serum levels of 25-hydroxy vitamin D in normal Biozzi and C57BL/6 mice and during the course of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE). Inflammation Research, 2013, 62, 659-667.	4.0	8
262	Disease modification in advanced MS: Focus on upper limb function. Multiple Sclerosis Journal, 2017, 23, 1956-1957.	3.0	8
263	Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 42, 102259.	2.0	8
264	The impact of social capital on patients with multiple sclerosis. Acta Neurologica Scandinavica, 2020, 142, 58-65.	2.1	8
265	Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. Journal of Medical Internet Research, 2021, 23, e29558.	4.3	8
266	Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. Journal of Neurology, 2020, 267, 2851-2864.	3.6	8
267	More to come: Humoral immune responses in MS. Journal of Neuroimmunology, 2011, 240-241, 13-21.	2.3	7
268	A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe. Multiple Sclerosis and Related Disorders, 2015, 4, 83-84.	2.0	7
269	Tackling comorbidity in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 17, 144-145.	2.0	7
270	Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study. Journal of Neurology, 2018, 265, 1795-1802.	3.6	7

#	Article	IF	Citations
271	Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731878376.	1.0	7
272	Social capital: Implications for neurology. Brain and Behavior, 2019, 9, e01169.	2.2	7
273	Detecting and predicting neutralization of alemtuzumab responses in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	7
274	Health-care disparities for people with multiple sclerosis. Lancet Neurology, The, 2020, 19, 207-208.	10.2	7
275	Predicting Multiple Sclerosis: Challenges and Opportunities. Frontiers in Neurology, 2021, 12, 761973.	2.4	7
276	PANDAS: overview of the hypothesis. Advances in Neurology, 2006, 99, 159-65.	0.8	7
277	Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of Neurology, 2022, 269, 5093-5104.	3.6	7
278	Web‐based assessment of Parkinson's prodromal markers identifies GBA variants. Movement Disorders, 2015, 30, 1002-1003.	3.9	6
279	How to refer to people with disease in research outputs: The disconnection between academic practise and that preferred by people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 10, 127-133.	2.0	6
280	Can we afford not to prevent MS-related disability?. Multiple Sclerosis Journal, 2017, 23, 1048-1049.	3.0	6
281	Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. Multiple Sclerosis and Related Disorders, 2017, 17, 172-176.	2.0	6
282	Cerebrospinal fluid NCAM levels are modulated by disease‐modifying therapies. Acta Neurologica Scandinavica, 2019, 139, 422-427.	2.1	6
283	Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 41, 102024.	2.0	6
284	GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains. Scientific Reports, 2020, 10, 1860.	3.3	6
285	Severe skin reactions associated with cladribine in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 43, 102140.	2.0	6
286	Gender issues during the times of COVID‐19 pandemic. European Journal of Neurology, 2021, 28, e73-e77.	3.3	6
287	Measuring treatment response to advance precision medicine for multiple sclerosis. Annals of Clinical and Translational Neurology, 2021, 8, 2166-2173.	3.7	6
288	Exercise training in multiple sclerosis. Lancet Neurology, The, 2022, 21, 313.	10.2	6

#	Article	IF	Citations
289	The role of antibody affinity for specific antigens in the differential diagnosis of inflammatory nervous system disorders. Journal of Neuroimmunology, 2006, 180, 29-32.	2.3	5
290	Developing Biomarkers for MS. Current Topics in Behavioral Neurosciences, 2014, 26, 179-194.	1.7	5
291	World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application. Multiple Sclerosis Journal, 2020, 26, 153-158.	3.0	5
292	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. Multiple Sclerosis Journal, 2021, 27, 922-932.	3.0	5
293	B cell therapy and the use of RNA-based COVID-19 vaccines. Multiple Sclerosis and Related Disorders, 2021, 49, 102887.	2.0	5
294	Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110576.	3.5	5
295	Age-specific effects of childhood body mass index on multiple sclerosis risk. Journal of Neurology, 2022, 269, 5052-5060.	3.6	5
296	The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis. European Journal of Neurology, 2022, 29, 2754-2760.	3.3	5
297	Multiple sclerosis and its pathophysiology. , 2002, , 1606-1619.		4
298	MSer â€" A new, neutral descriptor for someone with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 31-33.	2.0	4
299	Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?. Multiple Sclerosis and Related Disorders, 2015, 4, 88-91.	2.0	4
300	Time and brain health both matter in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 9, S1-S3.	2.0	4
301	Complexity of MS management in the current treatment era. Neurology, 2018, 90, 761-762.	1.1	4
302	Prevalence and demographics of multiple sclerosis-associated uveitis: a UK biobank study. Multiple Sclerosis and Related Disorders, 2020, 43, 102209.	2.0	4
303	Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110242.	1.0	4
304	Can rheumatologists stop causing demyelinating disease?. Multiple Sclerosis and Related Disorders, 2021, 53, 103057.	2.0	4
305	Optimising classification of Parkinsonâ€™s disease based on motor, olfactory, neuropsychiatric and sleep features. Npj Parkinson's Disease, 2021, 7, 87.	5.3	4
306	Remyelination trial failures: Repercussions of ignoring neurorehabilitation and exercise in repair. Multiple Sclerosis and Related Disorders, 2022, 58, 103539.	2.0	4

#	Article	IF	Citations
307	Multiple sclerosis is one disease. Multiple Sclerosis and Related Disorders, 2022, 63, 103961.	2.0	4
308	Optimising MS disease-modifying therapies: antibodies in perspective. Journal of Neurology, 2004, 251, v30-v35.	3.6	3
309	The REFLEX study: a missed opportunity?. Lancet Neurology, The, 2012, 11, 22-24.	10.2	3
310	TOWARDS AN ENDOPHENOTYPE IN MULTIPLE SCLEROSIS. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.147-e2.	1.9	3
311	Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta. Multiple Sclerosis Journal, 2018, 24, 1725-1736.	3.0	3
312	039–...Rates of lymphopenia in years 1–4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A16.2-A16.	1.9	3
313	Do we have equipoise when it comes to how we treat active multiple sclerosis?. Lancet Neurology, The, 2019, 18, 909-911.	10.2	3
314	Is the 'MS establishment' biased; the case for addressing gender inequality in the field of MS?. Multiple Sclerosis and Related Disorders, 2019, 28, 153-154.	2.0	3
315	Inclusion criteria used in trials of people with progressive multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 279-283.	3.0	3
316	Overview of Differences and Similarities of Published Mixed Treatment Comparisons on Pharmaceutical Interventions for Multiple Sclerosis. Neurology and Therapy, 2020, 9, 335-358.	3.2	3
317	Air pollution and multiple sclerosis risk. Multiple Sclerosis and Related Disorders, 2021, 48, 102797.	2.0	3
318	Human swayback disease: expanding the spectrum of diseases associated with abnormal copper metabolism. Journal of Neurology, 2001, 248, 707-707.	3.6	2
319	Simvastatin in patients with progressive multiple sclerosis. Lancet, The, 2014, 384, 952.	13.7	2
320	Systematic review and meta–analysis of salivary protein concentration in <scp>P</scp>arkinson's disease. Movement Disorders, 2015, 30, 1971-1972.	3.9	2
321	Why do you have to be lucky to get the MS treatment you deserve?. Multiple Sclerosis and Related Disorders, 2016, 8, A3-A4.	2.0	2
322	Are the high-costs of MS disease-modifying therapies justified?. Multiple Sclerosis and Related Disorders, 2018, 20, A3-A5.	2.0	2
323	Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. Multiple Sclerosis Journal, 2018, 24, 1883-1891.	3.0	2
324	Survival: the ultimate long-term outcome in multiple sclerosis. Brain, 2019, 142, 1166-1167.	7.6	2

#	ARTICLE	IF	CITATIONS
325	A cell-based assay for the detection of neutralizing antibodies against alemtuzumab. BioTechniques, 2020, 68, 185-190.	1.8	2
326	Is multiple sclerosis overdiagnosed?. Multiple Sclerosis and Related Disorders, 2021, 47, 102721.	2.0	2
327	Can serum glial fibrillary acidic protein (GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 50, 102931.	2.0	2
328	Evaluation of remote assessments for multiple sclerosis in an in-home setting. Multiple Sclerosis and Related Disorders, 2021, 54, 103125.	2.0	2
329	Remote testing of vitamin D levels across the UK MS populationâ€"A case control study. PLoS ONE, 2020, 15, e0241459.	2.5	2
330	Derisking CD20-therapies for long-term use. Multiple Sclerosis and Related Disorders, 2021, 57, 103418.	2.0	2
331	Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary. Neurodegenerative Disease Management, 2022, 12, 1-7.	2.2	2
332	Prevalence of disability improvement in relapsingâ€"remitting multiple sclerosis patients treated with cladribine tablets. European Journal of Neurology, 2022, 29, 2144-2147.	3.3	2
333	Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets. Frontiers in Immunology, 2021, 12, 763433.	4.8	2
334	Increased Urinary Neopterin Excretion in Vaccinated Adults. Pteridines, 1996, 7, 82-86.	0.5	1
335	ECTRIMS 2012: Treatment highlights. Multiple Sclerosis and Related Disorders, 2013, 2, 68-72.	2.0	1
336	Timing is everything in the treatment of multiple sclerosis. BMJ Case Reports, 2015, 2015, bcr2014208960-bcr2014208960.	0.5	1
337	How to start a blog. Practical Neurology, 2017, 17, 224-228.	1.1	1
338	Editorsâ€™ Welcome. Multiple Sclerosis and Related Disorders, 2017, 12, A1-A2.	2.0	1
339	Should our treatment target in MS include the intrathecal plasma cell response?. Multiple Sclerosis and Related Disorders, 2019, 27, A1-A2.	2.0	1
340	Ageing and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 38, 101953.	2.0	1
341	Digesting science: Developing educational activities about multiple sclerosis, prevention and treatment to increase the confidence of affected families. Multiple Sclerosis and Related Disorders, 2021, 47, 102624.	2.0	1
342	Amyloidoma mimicking multiple sclerosis. Practical Neurology, 2021, 21, 344-345.	1.1	1

#	Article	IF	Citations
343	Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report. Multiple Sclerosis and Related Disorders, 2021, 56, 103284.	2.0	1
344	Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. Multiple Sclerosis and Related Disorders, 2022, 57, 103409.	2.0	1
345	Antibodies to neurofilament light as potential biomarkers in multiple sclerosis. BMJ Neurology Open, 2021, 3, e000192.	1.6	1
346	Update on NHS Reset and Reform achievements in 2021. British Journal of Neuroscience Nursing, 2022, 18, S20-S24.	0.2	1
347	How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?. Multiple Sclerosis and Related Disorders, 2022, 63, 103803.	2.0	1
348	Onset of multiple sclerosis is preventable â€" time to act now!. Multiple Sclerosis and Related Disorders, 2022, 62, 103875.	2.0	1
349	Recent developments in oral medications for the treatment of multiple sclerosis. Future Neurology, 2010, 5, 167-172.	0.5	0
350	Cladribine to treat multiple sclerosis. , 0, , 358-369.		0
351	Emerging disease modifying treatmentsâ€"A therapeutics update from ECTRIMS/ACTRIMS, Amsterdam, 2011. Multiple Sclerosis and Related Disorders, 2012, 1, 56-58.	2.0	0
352	Editorial. Multiple Sclerosis and Related Disorders, 2013, 2, 153.	2.0	0
353	THINK OUTSIDE THE BOX, COLLAPSE THE BOX, AND TAKE A SHARP KNIFE TO IT!. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.83-e2.	1.9	0
354	IMMUNOCOMPETENT PMLâ€"AN IMMUNOLOGICAL SCOTOMA?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.16-e4.	1.9	0
355	SURVEY OF UK MEDICAL STUDENTS ON THE PERCEPTION OF NEUROLOGY. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.157-e4.	1.9	0
356	ALEMTUZUMAB IMPROVES 3-YEAR QUALITY OF LIFE IN CARE-MS II. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.9-e4.	1.9	0
357	Editorsâ€™ Welcome. Multiple Sclerosis and Related Disorders, 2015, 4, A1-A3.	2.0	0
358	ELEVATED SALIVARY DJ-1 IN PARKINSON'S DISEASE IS ASSOCIATED WITH ALTERED SALIVARY SECRETION. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.111-e4.	1.9	0
359	Editorsâ€™ Welcome. Multiple Sclerosis and Related Disorders, 2016, 7, A1-A2.	2.0	0
360	ALEMTUZUMAB IMPROVES EDSS FUNCTIONAL SYSTEMS SCORES IN RRMS. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.38-e1.	1.9	0

#	Article	IF	Citations
361	PO109â€¦Is there an ethnicity bias of access to multiple services in the nhs? â€" the barts health experience. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A40.2-A40.	1.9	0
362	PO138â€¦High disease activity in relapsing multiple sclerosis (rms). Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A49.1-A49.	1.9	0
363	PO137â€¦Efficacy of cladribine tablets in high disease activity rms. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A48.3-A49.	1.9	0
364	PO151â€¦Infections in patients with multiple sclerosis on alemtuzumab â€" should antibiotic prophylaxis be standard?. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A52.3-A53.	1.9	0
365	PO136â€¦Durable efficacy of cladribine tablets: clarity+extension. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A48.2-A48.	1.9	0
366	Editorsâ€™ Welcome. Multiple Sclerosis and Related Disorders, 2018, 20, A1-A2.	2.0	0
367	WED 186â€¦Effect of cladribine tablets on immune cells in patients with ms. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A26.2-A26.	1.9	0
368	WED 184â€¦Cladribine tablets in clarity patients with high disease activity ms. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A25.3-A26.	1.9	0
369	067â€¦Efficacy of cladribine tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the clarity and onward studies. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A27.2-A28.	1.9	0
370	Is cognitive impairment in multiple sclerosis reversible?. Multiple Sclerosis and Related Disorders, 2018, 23, A1.	2.0	0
371	Chronic-relapsing varicella zoster meningitis â€" Successfully treated with varicella vaccine. Journal of Infection, 2019, 79, 61-74.	3.3	0
372	The unintended consequences of NICE. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 247-248.	1.9	0
373	Distinguishing physiological versus pathological serum NfL levels in multiple sclerosis will require serial measurements. Multiple Sclerosis and Related Disorders, 2020, 46, 102477.	2.0	0
374	Regarding: Nicotinic acetylcholine receptors Î±7 and Î±9 modify tobacco smoke risk for multiple sclerosis. Multiple Sclerosis Journal, 2020, 27, 135245852096994.	3.0	0
375	WED 185â€¦Clarity: mri outcomes in high disease activity relapsing ms. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A26.1-A26.	1.9	0
376	THUR 192â€¦Yearly lymphopenia rates in cladribine tablets-treated rms patients. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A27.3-A28.	1.9	0
377	CLINICAL VIEWPOINT: Immunosuppression and COVID-19. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 2020, 19, 8-9.	0.1	0
378	Dare we mention the C-word?. Multiple Sclerosis and Related Disorders, 2020, 43, 102340.	2.0	0

#	ARTICLE	IF	CITATIONS
379	It is time to move to alternative clinical trial designs: Reconsidering the holy grail of trial methodology. Multiple Sclerosis and Related Disorders, 2021, 56, 103426.	2.0	0
380	Remote testing of vitamin D levels across the UK MS populationâ€"A case control study. , 2020, 15, e0241459.		0
381	Remote testing of vitamin D levels across the UK MS populationâ€"A case control study. , 2020, 15, e0241459.		0
382	Remote testing of vitamin D levels across the UK MS populationâ€"A case control study. , 2020, 15, e0241459.		0
383	Remote testing of vitamin D levels across the UK MS populationâ€"A case control study. , 2020, 15, e0241459.		0
384	High efficacy treatment is not enough in MS: Socioeconomic factors are key to improving outcomes. Multiple Sclerosis and Related Disorders, 2022, 61, 103816.	2.0	0
385	Personalised immunotherapy in active multiple sclerosis using injectable cladrib- ine: Follow-up of the BartsMS cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A2.3-A2.	1.9	0
386	021â€… Determinants of natalizumab-associated PML outcomes. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A20.1-A20.	1.9	0
387	229â€… Developing novel smell test for Parkinsonâ€™s disease using microencapsulation of essential oils in alginate. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A79.3-A79.	1.9	0
388	026â€… Gene-environment interactions in multiple sclerosis: a UK Biobank study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A21.3-A22.	1.9	0
389	091â€… Evaluation of remote assessments for multiple sclerosis in a real-world setting. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A129.1-A129.	1.9	0
390	043â€… Efficacy of siponimod in secondary progressive multiple sclerosis with active disease: EXPAND study subgroup analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A27.1-A27.	1.9	0
391	022â€… Updated safety of cladribine tablets in multiple sclerosis patients: integrated safety analysis and post-approval data. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A20.2-A20.	1.9	0
392	045â€… Effect of siponimod on cortical grey matter and thalamic volume in secondary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A27.3-A27.	1.9	0
393	015â€… Reduced risk of secondary progressive multiple sclerosis by treatment with clad- ribine tablets: CLARITY study analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A18.2-A18.	1.9	0
394	018â€… Disease control beyond NEDA: the value of non-clinical measures to determine treatment response to natalizumab. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A19.1-A19.	1.9	0
395	211â€… The prevalence and characteristics of multiple sclerosis-associated uveitis in UK biobank. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A74.2-A74.	1.9	0
396	120â€… The impact of socioeconomic status and comorbidities on emergency admissions in patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A138.3-A138.	1.9	0

#	Article	IF	Citations
397	Parkinson's disease determinants, prediction and gene-environment interac- tions: a UK Biobank study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A7.3-A8.	1.9	0
398	EBV as the "gluten of MS" hypothesis provides a rationale for trialing antiviral therapies. Multiple Sclerosis and Related Disorders, 2022, 64, 104007.	2.0	0